Jubilant Ingrevia Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Highest revenue in 14 quarters, with volume-led recovery: Revenue reached ₹1,179 cr, up 12% YoY on 10% volume growth, while EBITDA grew 11% YoY and PAT jumped 84% QoQ, all achieved with zero production loss during the Middle East crisis.
• Pinnacle Journey is delivering structural change: EBITDA has grown ~33% in two years, the portfolio mix has shifted to 85%+ specialty and nutrition, and Specialty EBITDA nearly doubled, even as pricing remained tough.
• Acetyls is set up for a strong Q1 FY27: The company locked in raw materials at favorable prices when the Middle East conflict began, and European competitor force majeures have opened a market-share opportunity with customers already qualified.
• CDMO is the growth engine management won't yet size: The pipeline has expanded 3x in two years, 70% of pharma opportunities are non-Pyridine, and new contracts ramp to 80%+ of peak revenue by year three, but absolute revenue and FY27 contribution remain undisclosed.
• What to watch next quarter: Whether the acetyls spread benefit materializes at the promised scale, the pace of human-grade B3 plant ramp-up toward 40–50% of peak volumes, and any announcement on the large late-stage CDMO opportunity.

Pinnacle Journey: The Structural Shift

• Two-year scorecard: EBITDA grew ~33% despite tough demand and declining prices, with the Q4 FY26 run-rate EBITDA sitting 70%+ higher than Q4 FY24. The portfolio mix has decisively tilted: Specialty and Nutrition now contribute 85%+ of EBITDA, and Specialty EBITDA almost doubled over the two years.
• Balance sheet efficiency improved: Net working capital tightened to 59 days, reflecting better cost structure and working capital discipline alongside the growth.
• FY30 ambition intact: Management remains confident of hitting 3x revenue and 4x EBITDA targets by FY30, with 20–25% annual EBITDA growth keeping the company on track and some inorganic contribution assumed.
• Vertical reorganization executed: The company transitioned to a vertical structure covering nutrition, pharma, agro, cosmetics, industrial and semicon segments, and made key senior hires across supply chain, manufacturing, HR, businesses, design and technology to support focused growth.

Shyam Bhartia: "Early outcomes of our Pinnacle Journey are clearly visible in our performance with strong EBITDA growth and improving portfolio mix, enhanced customer relationship and a robust opportunity pipeline, more efficient cost structure and balance sheet."

Acetyls: Spread Tailwind and European Opportunity

• Raw material agility paid off: When the Middle East war began in late February, raw material prices escalated. The company locked in raw material at the right price, benefits started flowing in Q4 FY26 and are expected to continue strongly into Q1 FY27.
• European competitors sidelined: European acetyls competitors announced force majeure due to mechanical failures. Jubilant's acetyls team has already qualified products with almost every European customer, positioning the company to gain volumes and market share in Europe this year.
• Pricing outlook supportive: Rising acetic acid prices are setting a favorable pricing outlook, adding to the spread benefit from locked-in raw material costs.
• Domestic demand also supportive: Chemical Intermediates revenue grew 15% YoY and 10% QoQ, with domestic volumes improving on strong agrochemical and paracetamol demand.

CDMO: The Undisclosed Growth Engine

• Pipeline has expanded 3x in two years: The pharma CDMO pipeline now spans innovators and Tier 1 CDMOs, with 70% of opportunities being non-Pyridine based, signaling broad-based capability recognition beyond the company's historical chemistry.
• Ramp-up profile is predictable: At the portfolio level, new CDMO opportunities are expected to deliver 20–25% of peak revenue in year one, 50–60% by year two, and 80%+ by year three, giving visibility into how the pipeline converts to revenue over time.
• Bharuch plant commissioned in record time: The new CDMO facility was built and commissioned in 14 months and has already passed a successful USFDA audit, adding capacity to capture the growing pipeline.
• Revenue and size remain undisclosed: Management declined to disclose the exact size of the CDMO business, stating only that it has been growing 30–40% every year, and would not break out how much is classified in Nutrition versus Specialty Chemicals.
• One large late-stage opportunity pending: A significant CDMO opportunity is in the hopper; management will announce it to the market if and when secured, but gave no timeline.
• Pharma CDMO ambition: The business targets reaching at least 3x to 4x of its current size, with some tracked opportunities capable of delivering nonlinear growth in the outer years of the Pinnacle Journey.

Deepak Jain: "Only 25% to 30% of this pipeline we have created in pharma is Pyridine-based, 70% is non-Pyridine."

Specialty Chemicals: Margin Resilience and Pricing Dynamics

• Volume recovery driving growth: Specialty Chemicals revenue reached ₹516 cr, up 6% YoY and 13% QoQ, with strong volume growth in Pyridine and derivatives and steady performance in Fine Chemicals and Diketene derivatives.
• EBITDA margin held at 27% for six straight quarters: After adjusting for corporate overheads, the margin sits at ~25%, with fast CDMO growth acting as a positive force that balances negative pressure from trading costs and derivatives. Cost optimization efforts continue.
• Pyridine and beta-picoline move inversely: Pyridine prices are currently at rock bottom while beta-picoline prices are at the highest level seen in years. The two products balance each other out, helping manage overall volatility in the portfolio.
• Large agro contract is protected: The company has an understanding and contractual commitment from the customer that any volume shortfall will be made whole, so bottom-line projections remain covered.
• Margin sustainability expected: Management expects Specialty Chemicals EBITDA margin to remain at 25%+ going forward, supported by CDMO mix improvement and ongoing cost optimization.

Deepak Jain: "Right now, as we speak, for Pyridine prices, they are very low, in fact, at the rock bottom right now. And while the beta-picoline prices are at the highest level, higher than what at least I have seen even in the last years."

Nutrition: Volume-Led Recovery and New Capacity

• Strong recovery driven by volumes: Nutrition revenue grew 21% YoY and 15% QoQ to ₹230 cr, with EBITDA of ₹32 cr up 42% QoQ and margin at 14%. Growth was led by niacinamide supported by cosmetics demand, while choline improved with a surge in exports to Europe.
• Human-grade B3 plant ramping in two speeds: The PC-grade niacinamide side scaled very fast and is already at ~50% of estimated volumes. The Niacin side started later, so ramp-up is gradual, with a projection to reach 40–50% of peak-level volumes this year.
• Remidex Pharma acquisition closed: The deal strengthens the Human Nutrition premixes portfolio, providing forward integration into premix and specialty products for the human nutrition segment.
• Rest of World gaining traction: Revenue growth outside India is being driven by good traction in Japan, Korea and Southeast Asian markets, particularly in Nutrition and Personal Care businesses.

Guidance & Commitments

Key Metrics